Publications by authors named "Harold Burstein"

Claim this Profile
C
Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study.
Lorenzo Gerratana, Carolina Reduzzi, Yue Ren, Rinath Jeselsohn, Reshma L Mahtani, Harold J Burstein

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.
William J Gradishar, Meena S Moran, Jame Abraham, Vandana Abramson, Rebecca Aft, Harold J Burstein

J Natl Compr Canc Netw· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT.
Karin Ribi, Bernard F Cole, Gini F Fleming, Barbara A Walley, Prudence A Francis, Harold J Burstein

Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical Trials.
Dario Trapani, Qingchun Jin, Kathy D Miller, Hope S Rugo, Katherine E Reeder-Hayes, Harold J Burstein

Clin Breast Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor-Positive Breast Cancer: ASCO Guideline Clinical Insights.
Igor Makhlin, Lesley Fallowfield, N Lynn Henry, Harold J Burstein, Mark R Somerfield

JCO Oncol Pract· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anthracyclines in Early Breast Cancer: The Long Goodbye.
Thomas Grinda, Harold J Burstein

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, Chau Dang, Denise A Yardley, Harold J Burstein

J Clin Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy for Early-Stage Triple-Negative Breast Cancer.
Harold J Burstein

N Engl J Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation After Implant-Based Reconstruction: A Randomized Clinical Trial.
Julia S Wong, Hajime Uno, Angela C Tramontano, Lauren Fisher, Catherine V Pellegrini, Harold J Burstein

JAMA Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response.
Carmine Valenza, Dario Trapani, Sibylle Loibl, Stephen K L Chia, Harold J Burstein

J Clin Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer.
Luca Boscolo Bielo, Dario Trapani, Eleonora Nicolò, Carmine Valenza, Lorenzo Guidi, Harold J Burstein

Cancer Treat Rev· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
William J Gradishar, Meena S Moran, Jame Abraham, Vandana Abramson, Rebecca Aft, Harold J Burstein

J Natl Compr Canc Netw· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer.
Erica L Mayer, Yue Ren, Nikhil Wagle, Reshma Mahtani, Cynthia Ma, Harold J Burstein

J Clin Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining the Biology of Estrogen Receptor-Low-Positive Breast Cancer.
Tessa Higgins, Olga Kantor, Beth Harrison, Julia Giordano, Monica McGrath, Harold J Burstein

Ann Surg Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.
Harold J Burstein, Angela DeMichele, Lesley Fallowfield, Mark R Somerfield, N Lynn Henry

J Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.
Erica L Mayer, Nabihah Tayob, Siyang Ren, Jennifer J Savoie, David R Spigel, Harold J Burstein

Breast Cancer Res Treat· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.
Georg Pfeiler, Dominik Hlauschek, Erica L Mayer, Christine Deutschmann, Stephanie Kacerovsky-Strobl, Harold Burstein

J Clin Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy.
Christina Mayerhofer, Mina S Sedrak, Judith O Hopkins, Tianyu Li, Nabihah Tayob, Harold J Burstein

J Natl Cancer Inst· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying Patterns and Barriers in OncotypeDX Recurrence Score Testing in Older Patients With Early-Stage, Estrogen Receptor-Positive Breast Cancer: Implications for Guidance and Reimbursement.
Dario Trapani, Qingchun Jin, Caroline C Block, Rachel A Freedman, Nancy U Lin, Harold J Burstein

JCO Oncol Pract· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Testing for Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.
Harold J Burstein, Angela DeMichele, Mark R Somerfield, N Lynn Henry,

J Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.
William J Gradishar, Meena S Moran, Jame Abraham, Vandana Abramson, Rebecca Aft, Harold J Burstein

J Natl Compr Canc Netw· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.
Olivia Pagani, Barbara A Walley, Gini F Fleming, Marco Colleoni, István Láng, Harold J Burstein

J Clin Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Sara M Tolaney, Paolo Tarantino, Noah Graham, Nabihah Tayob, Laia Parè, Harold J Burstein

Lancet Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
Heather A Parsons, Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Harold J Burstein

medRxiv· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer.
Albert Grinshpun, Sara M Tolaney, Harold J Burstein, Rinath Jeselsohn, Erica L Mayer

NPJ Breast Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis